Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00991315
Recruitment Status : Terminated (Specimens are now collected through the BRS protocol.)
First Posted : October 8, 2009
Last Update Posted : October 5, 2020
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Information provided by (Responsible Party):
Isaac Yi Kim, MD, PhD, MBA, Rutgers, The State University of New Jersey

Brief Summary:
The primary objective of this study is to collect material for study's to assess mechanisms of tumor progression, mechanisms of resistance, isolation of stem cells and biologic markers in tissue, serum and peripheral blood mononuclear cells.

Condition or disease
Prostate Cancer

Layout table for study information
Study Type : Observational
Actual Enrollment : 126 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Assessment of Tumor Resistance and Stem Cells in Prostate Cancer
Actual Study Start Date : December 12, 2008
Actual Primary Completion Date : April 10, 2017
Actual Study Completion Date : April 10, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer




Primary Outcome Measures :
  1. Collection and freezing of tumor samples [ Time Frame: 5 years ]

Biospecimen Retention:   Samples With DNA
Samples will be collected at time of TURP and will be deidentified and processed by standard procedures.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patient undergoing a routine prostatectomy or TURP (transurethral resection of the prostate) may be asked to participate
Criteria

DISEASE CHARACTERISTICS:

  • Undergoing routine prostatectomy or transurethral resection of the prostate (TURP)

PATIENT CHARACTERISTICS:

5.1.1 Patient is undergoing routine prostatectomy or TURP.

5.1.2 Patient is ≥ 18 years old.

5.1.3 Patient must give informed consent.

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00991315


Locations
Layout table for location information
United States, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903
Sponsors and Collaborators
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Investigators
Layout table for investigator information
Principal Investigator: Isaac Kim, MD, PhD Rutgers Cancer Institute of New Jersey
Layout table for additonal information
Responsible Party: Isaac Yi Kim, MD, PhD, MBA, Associate Professor, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier: NCT00991315    
Other Study ID Numbers: 080809
P30CA072720 ( U.S. NIH Grant/Contract )
0220080275 ( Other Identifier: IRB # )
First Posted: October 8, 2009    Key Record Dates
Last Update Posted: October 5, 2020
Last Verified: September 2020
Keywords provided by Isaac Yi Kim, MD, PhD, MBA, Rutgers, The State University of New Jersey:
prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases